AbbVie Inc. $ABBV is BDF Gestion’s 10th Largest Position

BDF Gestion grew its holdings in AbbVie Inc. (NYSE:ABBV) by 28.9% during the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 44,504 shares of the company’s stock after purchasing an additional 9,982 shares during the period. AbbVie comprises approximately 1.2% of BDF Gestion’s holdings, making the stock its 10th largest holding. BDF Gestion’s holdings in AbbVie were worth $10,169,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also made changes to their positions in the company. Chelsea Counsel Co. bought a new position in shares of AbbVie in the third quarter worth about $26,000. Texas Capital Bancshares Inc TX bought a new stake in AbbVie during the 3rd quarter valued at about $31,000. Evolution Wealth Management Inc. purchased a new stake in AbbVie in the 2nd quarter valued at about $26,000. Caitlin John LLC purchased a new stake in AbbVie in the 3rd quarter valued at about $33,000. Finally, Redmont Wealth Advisors LLC bought a new position in AbbVie in the 3rd quarter worth about $41,000. 70.23% of the stock is currently owned by institutional investors.

AbbVie Stock Down 0.1%

Shares of ABBV stock opened at $204.89 on Tuesday. The firm has a market cap of $362.29 billion, a price-to-earnings ratio of 86.82, a PEG ratio of 0.71 and a beta of 0.34. AbbVie Inc. has a 52-week low of $164.39 and a 52-week high of $244.81. The company’s 50 day moving average is $222.79 and its 200 day moving average is $224.80.

AbbVie (NYSE:ABBV) last posted its earnings results on Wednesday, February 4th. The company reported $2.71 earnings per share for the quarter, topping analysts’ consensus estimates of $2.65 by $0.06. The company had revenue of $16.62 billion during the quarter, compared to analyst estimates of $16.39 billion. AbbVie had a negative return on equity of 1,579.75% and a net margin of 6.91%.AbbVie’s revenue was up 10.0% on a year-over-year basis. During the same quarter in the prior year, the business earned $2.16 earnings per share. AbbVie has set its FY 2026 guidance at 14.370-14.570 EPS and its Q1 2026 guidance at 2.970-3.010 EPS. Analysts anticipate that AbbVie Inc. will post 12.31 EPS for the current fiscal year.

AbbVie Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Friday, May 15th. Investors of record on Wednesday, April 15th will be paid a dividend of $1.73 per share. This represents a $6.92 dividend on an annualized basis and a dividend yield of 3.4%. The ex-dividend date is Wednesday, April 15th. AbbVie’s dividend payout ratio is 293.22%.

Analyst Ratings Changes

A number of equities analysts have recently commented on the stock. Berenberg Bank set a $275.00 target price on shares of AbbVie in a research report on Tuesday, January 20th. Weiss Ratings reissued a “hold (c)” rating on shares of AbbVie in a research note on Wednesday, January 21st. HSBC upgraded AbbVie from a “hold” rating to a “buy” rating and raised their price objective for the stock from $225.00 to $265.00 in a report on Wednesday, December 10th. BMO Capital Markets reaffirmed an “outperform” rating on shares of AbbVie in a research report on Monday, March 9th. Finally, Piper Sandler upped their target price on AbbVie from $289.00 to $299.00 and gave the stock an “overweight” rating in a report on Wednesday, February 18th. Two investment analysts have rated the stock with a Strong Buy rating, fourteen have given a Buy rating and nine have given a Hold rating to the company. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average target price of $253.15.

Insider Transactions at AbbVie

In related news, SVP David Ryan Purdue sold 5,230 shares of the firm’s stock in a transaction dated Wednesday, March 4th. The stock was sold at an average price of $233.56, for a total transaction of $1,221,518.80. Following the sale, the senior vice president owned 2,654 shares of the company’s stock, valued at $619,868.24. This trade represents a 66.34% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, EVP Perry C. Siatis sold 22,381 shares of AbbVie stock in a transaction dated Wednesday, February 25th. The shares were sold at an average price of $230.00, for a total value of $5,147,630.00. Following the completion of the transaction, the executive vice president owned 38,137 shares in the company, valued at $8,771,510. This trade represents a 36.98% decrease in their position. The disclosure for this sale is available in the SEC filing. 0.08% of the stock is owned by company insiders.

About AbbVie

AbbVie is a global, research-driven biopharmaceutical company that was created as a spin-off from Abbott Laboratories in 2013 and is headquartered in North Chicago, Illinois. The company focuses on discovering, developing and commercializing therapies for complex and often chronic medical conditions. Its operations span research and development, manufacturing, regulatory affairs and commercialization, with an emphasis on bringing specialty medicines to market across multiple therapeutic areas.

AbbVie’s product portfolio and pipeline cover several major therapeutic categories, including immunology, oncology, neuroscience, virology and women’s health.